Literature DB >> 16452544

Predictors of abnormal glucose metabolism in women with polycystic ovary syndrome.

Matthias Möhlig1, Joachim Spranger, Michael Ristow, Andreas F H Pfeiffer, Thilo Schill, Hans W Schlösser, Lothar Moltz, Georg Brabant, Christof Schöfl.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is a risk factor for type 2 diabetes mellitus and screening for abnormal glucose metabolism has been recommended by an oral glucose tolerance test (OGTT). This procedure is time-consuming and inconvenient, limiting its general use. Therefore, an easy method is wanted to separate PCOS women with normal from those with potentially abnormal glucose metabolism.
DESIGN: Simple parameters obtained from 101 consecutive PCOS patients were assessed by receiver operating curve analysis for their ability to predict abnormal glucose metabolism.
RESULTS: Comparing discriminating parameters at defined sensitivities revealed that, assessed by homeostasis model assessment (HOMA), insulin resistance (HOMA%S) had the highest specificity. At a cut-off point of 73.1%, HOMA%S had a sensitivity of 95.5% and a specificity of 51.9%. Applying this cut-off separated 59 women who had a high probability of abnormal glucose metabolism from 42 women who were at low risk (less than 2.5%). Fasting insulin was the second-best parameter and had a similar specificity. A screening strategy which applies HOMA%S or fasting insulin could almost halve the number of OGTTs by directing them to those PCOS women most likely to be suffering from abnormal glucose metabolism. The negative predictive value of this strategy was 97%. The strategy was tested and confirmed in a second and independent cohort of 264 PCOS women.
CONCLUSIONS: HOMA%S, or to a lesser extent fasting insulin, appears to allow for stratified metabolic screening of PCOS women with OGTT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452544     DOI: 10.1530/eje.1.02095

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Novel diagnostics of metabolic dysfunction detected in breath and plasma by selective isotope-assisted labeling.

Authors:  Julia A Haviland; Marco Tonelli; Dermot T Haughey; Warren P Porter; Fariba M Assadi-Porter
Journal:  Metabolism       Date:  2012-02-02       Impact factor: 8.694

2.  Insulin resistance influences central opioid activity in polycystic ovary syndrome.

Authors:  Alison Berent-Spillson; Tiffany Love; Rodica Pop-Busui; MaryFran Sowers; Carol C Persad; Kathryn P Pennington; Aimee D Eyvazaddeh; Vasantha Padmanabhan; Jon-Kar Zubieta; Yolanda R Smith
Journal:  Fertil Steril       Date:  2011-04-12       Impact factor: 7.329

3.  The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome.

Authors:  Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung; Wha Young Cho
Journal:  Endocrine       Date:  2009-08-14       Impact factor: 3.633

4.  Using simple clinical measures to predict insulin resistance or hyperglycemia in girls with polycystic ovarian syndrome.

Authors:  Melanie Cree-Green; Ninghe Cai; Jessica E Thurston; Gregory V Coe; Lindsay Newnes; Yesenia Garcia-Reyes; Amy D Baumgartner; Laura Pyle; Kristen J Nadeau
Journal:  Pediatr Diabetes       Date:  2018-10-09       Impact factor: 4.866

5.  Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians.

Authors:  Thomas Bobbert; Franziska Schwarz; Antje Fischer-Rosinsky; Andreas F H Pfeiffer; Matthias Möhlig; Knut Mai; Joachim Spranger
Journal:  Diabetes Care       Date:  2012-08-28       Impact factor: 19.112

6.  Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?

Authors:  E Moll; J C Korevaar; P M M Bossuyt; F van der Veen
Journal:  Hum Reprod       Date:  2008-05-17       Impact factor: 6.918

7.  Leptin-adiponectin imbalance as a marker of metabolic syndrome among Chinese children and adolescents: The BCAMS study.

Authors:  Ge Li; Linxin Xu; Yanglu Zhao; Lujiao Li; Junling Fu; Qian Zhang; Naishi Li; Xinhua Xiao; Changhong Li; Jie Mi; Shan Gao; Ming Li
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.